Serum neurofilament light as a biomarker in progressive multiple sclerosis
暂无分享,去创建一个
D. Arnold | W. Carroll | R. Fox | M. Comabella | J. Kuhle | C. Teunissen | R. Furlan | D. Leppert | R. Kapoor | F. Sellebjerg | T. Plavina | Kathryn E Smith | C. Harp | F. von Raison | M. Allegretta | C. Sincock | Ilir Topalli | Elizabeth Walker | E. Walker
[1] P. F. Kauff. Group , 2000, Elegant Design.
[2] R. Henry,et al. Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years. , 2019, JAMA neurology.
[3] K. Blennow,et al. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. , 2019, JAMA neurology.
[4] B. Bielekova,et al. CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage , 2019, Multiple sclerosis.
[5] M. Sormani,et al. Blood neurofilament light as a potential endpoint in Phase 2 studies in MS , 2019, Annals of clinical and translational neurology.
[6] L. Kappos,et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response , 2019, Neurology.
[7] Nick C Fox,et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease , 2019, Nature Medicine.
[8] K. Blennow,et al. Commutability of the certified reference materials for the standardization of β-amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and β-amyloid 1-40 measurements , 2018, Clinical chemistry and laboratory medicine.
[9] Ankur Sharma. Strategic platform selection and validation of biomarker assays to measure serum neurofilament light and heavy chain in multiple sclerosis , 2018 .
[10] Ludwig Kappos,et al. Neurofilaments as biomarkers in neurological disorders , 2018, Nature Reviews Neurology.
[11] Sridar Narayanan,et al. Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis , 2018, The New England journal of medicine.
[12] K. Blennow,et al. Evidence for sex difference in the CSF/plasma albumin ratio in ~20 000 patients and 335 healthy volunteers , 2018, Journal of cellular and molecular medicine.
[13] P. Andersen,et al. Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion , 2018, Annals of neurology.
[14] K. Blennow,et al. Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod , 2018, Multiple sclerosis.
[15] Ludwig Kappos,et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis , 2018, Brain : a journal of neurology.
[16] L. Kappos,et al. Siponimod Reduces Neurofilament Light Chain Blood Levels in Secondary Progressive Multiple Sclerosis Patients (S8.006) , 2018, Neurology.
[17] Sara Llufriu,et al. Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome , 2018, Brain : a journal of neurology.
[18] Ian A. Watson,et al. Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis , 2017, Clinical and translational science.
[19] K. Blennow,et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein , 2017, Neurology.
[20] D. Menon,et al. Serial Sampling of Serum Protein Biomarkers for Monitoring Human Traumatic Brain Injury Dynamics: A Systematic Review , 2017, Front. Neurol..
[21] Ludwig Kappos,et al. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis , 2017, Annals of neurology.
[22] Alzheimer's Disease Neuroimaging Initiative. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease , 2017 .
[23] Vicente E. Torres,et al. A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease , 2017, Kidney international reports.
[24] Gavin Giovannoni,et al. Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. , 2017, Multiple sclerosis and related disorders.
[25] Henrik Zetterberg,et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa , 2016, Clinical chemistry and laboratory medicine.
[26] J. Long,et al. Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis. , 2016, Contemporary clinical trials.
[27] M. Staufenbiel,et al. Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases , 2016, Neuron.
[28] M. Staufenbiel,et al. Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases , 2016, Neuron.
[29] H. Siebner,et al. Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis , 2016, Multiple sclerosis.
[30] K. Blennow,et al. Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study , 2015, EBioMedicine.
[31] A. Thompson,et al. Progressive MS: from pathophysiology to drug discovery , 2015, Multiple sclerosis.
[32] D Polhamus,et al. The future is now: Model‐based clinical trial design for Alzheimer's disease , 2015, Clinical pharmacology and therapeutics.
[33] Richard Nicholas,et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial , 2014, The Lancet.
[34] H. Siebner,et al. Natalizumab in progressive MS , 2014, Neurology.
[35] H. Zetterberg,et al. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis , 2014, Multiple sclerosis.
[36] H. Larsson,et al. Relationship between Cerebrospinal Fluid Biomarkers for Inflammation, Demyelination and Neurodegeneration in Acute Optic Neuritis , 2013, PloS one.
[37] Ludwig Kappos,et al. Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases , 2013, PloS one.
[38] M. Sormani,et al. MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials , 2013, The Lancet Neurology.
[39] L. Kappos,et al. A comparative study of CSF neurofilament light and heavy chain protein in MS , 2013, Multiple sclerosis.
[40] O. Ciccarelli,et al. Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS , 2012, Multiple sclerosis.
[41] David H. Miller,et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial , 2010, The Lancet Neurology.
[42] A. Thompson,et al. Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis , 2009, Neurology.
[43] L. Rosengren,et al. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS , 2003, Neurology.
[44] N. Norgren,et al. Monoclonal antibodies selective for low molecular weight neurofilaments. , 2002, Hybridoma and hybridomics.